{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-004587","form_type":"8-K","ticker":"GTBP","cik":"0000109657","company_name":"GT Biopharma, Inc.","filed_at":"2024-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.354717+00:00","generated_at":"2026-06-06T10:38:57.429496+00:00","sec_items":["3.03","5.03","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"GT Biopharma announces 1-for-30 reverse stock split to regain Nasdaq compliance","bullets":["Reverse split ratio 1:30 effective 5:00 PM ET Feb 2, 2024; post-split trading begins Feb 5.","Outstanding shares reduced from ~41.4M to ~1.38M; authorized shares unchanged at 250M.","No fractional shares issued; stockholders receive cash for fractional shares.","Proportionate adjustments to outstanding stock options and equity awards.","Action intended to regain Nasdaq $1.00 minimum bid price; ticker remains GTBP."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-004587","json":"https://secwatch.observer/filing/0001493152-24-004587.json","markdown":"https://secwatch.observer/filing/0001493152-24-004587.md","text":"https://secwatch.observer/filing/0001493152-24-004587.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/109657/000149315224004587/0001493152-24-004587-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/109657/000149315224004587/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T10:38:57.429496+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ec7dd181e4bc574622609cbc12205411b75eaa21","claim":"GT Biopharma, Inc.: Filed Certificate of Amendment to effect a 1-for-30 reverse stock split of common stock, effective February 2, 2024, with reduced outstanding shares and unchanged authorized shares (effective 2024-02-02).","evidence_excerpt":"On February 1, 2024, GT Biopharma, Inc. filed a Certificate of Amendment of our Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a reverse stock split of our common stock, par value $0.001 per share, at a ratio of 1-for-30.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/109657/000149315224004587/0001493152-24-004587-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-02-02"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}